Peptide Related Substances Analysis: Principles, Methods, and Regulatory Applications

Peptide related substances analysis is a cornerstone of pharmaceutical quality control, enabling the accurate detection, identification, and quantification of structurally related impurities in peptide active pharmaceutical ingredients and drug products. Using orthogonal techniques such as RP-HPLC, LC-MS, ion-exchange chromatography, and capillary electrophoresis, accredited third-party laboratories help manufacturers satisfy ICH and pharmacopoeial requirements. This article reviews the impurity landscape, sample types, testing items, analytical methods, and practical applications of related substances testing for therapeutic peptides.

Technical Overview

Therapeutic peptides represent one of the fastest-growing classes of pharmaceutical active substances, with applications spanning metabolic disease, oncology, immunology, and cardiovascular medicine. Because peptides are structurally complex and often produced through multi-step solid-phase peptide synthesis (SPPS) or recombinant expression, they are inherently accompanied by a diverse population of structurally related impurities. These impurities, collectively termed related substances, may be process-related residuals or degradation products formed during manufacture, storage, or use.

Related substances analysis for peptides is technically demanding because most impurities share the parent peptide's amino acid backbone, similar molecular weight, and comparable chromatographic behavior. Many impurities differ from the active substance by only a single residue, a modified side chain, or a stereochemical inversion. A robust related substances strategy therefore requires high-resolution separation coupled with mass-sensitive and structure-confirming detectors.

The regulatory framework for peptide related substances draws on ICH Q3A(R2) and Q3B(R2) for impurity thresholds, ICH Q2(R2) for analytical method validation, ICH Q1A(R2) for stability testing, and ICH Q6B for specifications of biotechnology-derived substances. Pharmacopoeial monographs and general chapters in the USP, Ph. Eur., JP, and ChP provide additional product-specific acceptance criteria. Manufacturers frequently engage accredited third-party laboratories operating under ISO/IEC 17025 quality systems to perform these studies in support of regulatory submissions.

Testing Samples

Synthetic Peptide APIs

Peptides manufactured by solid-phase or liquid-phase synthesis constitute the largest sample category. Typical analytes include linear peptides of 2 to 60 amino acids, disulfide-rich peptides, and long-acting analogues such as GLP-1 receptor agonists. Process-related impurities such as deletion sequences, incompletely deprotected species, and capping failures are characteristic of this sample type.

Recombinant and Semi-Synthetic Peptides

Peptides expressed in microbial or mammalian host systems may contain truncation variants, N-terminal variants, oxidized or deamidated forms, and residual transformation-related impurities introduced during enzymatic or chemical cleavage steps. Related substances testing for these samples often integrates peptide mapping with high-resolution mass spectrometry.

Peptide Drug Products

Injectable solutions, lyophilized powders, suspensions, and nasal or oral formulations are tested for degradation products that arise from hydrolysis, oxidation, isomerization, and interaction with excipients, container closure systems, or headspace oxygen. Finished-product testing evaluates impurity growth relative to the drug substance and against shelf-life acceptance criteria.

Conjugated and Specialty Peptides

PEGylated peptides, lipidated peptides, peptide-drug conjugates, cyclic peptides, and peptide mixtures require tailored chromatographic and mass spectrometric strategies to resolve conjugation heterogeneity, linker-related species, and macrocycle stereoisomers alongside classical related substances.

Testing Items

Related substances analysis for peptides typically encompasses the following categories of process-related impurities:

• Deletion sequences arising from incomplete amino acid coupling
• Truncated sequences from premature chain termination
• Insertion sequences from double coupling of a single residue
• Incompletely deprotected species retaining side-chain protecting groups
• Capping-related by-products and acetylated side products
• Racemized or epimerized variants containing D-amino acid residues
• Adducts formed with coupling reagents, scavengers, or cleavage reagents

Degradation-related testing items include:

• Oxidation products, principally of methionine, tryptophan, histidine, and cysteine residues
• Deamidation products of asparagine and glutamine residues
• Aspartic acid isomerization and succinimide intermediates
• Peptide bond hydrolysis fragments
• Diketopiperazine formation at N-terminal sequences
• Disulfide scrambling and mismatched disulfide isomers
• Covalent dimers, oligomers, and non-covalent aggregates

Reporting typically covers the main peak purity, each specified impurity against a qualified reference, the largest unspecified impurity, and total related substances, all expressed as area percentage or mass percentage relative to the peptide active substance.

Testing Methods

Reversed-Phase HPLC

RP-HPLC with UV detection is the primary compendial method for peptide related substances. Gradient elution using C18 or phenyl columns with TFA- or formic-acid-modified mobile phases provides high peak capacity for separating closely related species. Method parameters including column temperature, organic modifier, and gradient slope are systematically optimized to resolve critical pairs such as deamidated and oxidized variants from the main peak.

LC-MS and High-Resolution Mass Spectrometry

Coupling liquid chromatography to single-quadrupole, triple-quadrupole, or high-resolution accurate-mass spectrometry enables mass confirmation of every resolved impurity peak. MS/MS fragmentation localizes modifications to specific residues, distinguishing, for example, Met oxidation from Trp oxidation, and identifying deletion sequences by their characteristic mass shifts.

Ion-Exchange Chromatography

IEX-HPLC separates charge variants such as deamidated species, acetylated by-products, and N-terminal variants that may co-elute in reversed-phase mode. It serves as a powerful orthogonal method for confirming method specificity and peak purity.

Size-Exclusion Chromatography

SEC quantifies dimeric, oligomeric, and aggregated related substances that are not reliably measured under denaturing reversed-phase conditions, supporting aggregate control strategies for peptide drug products.

Capillary Electrophoresis

Capillary zone electrophoresis and micellar electrokinetic chromatography offer complementary separations based on charge-to-mass ratio, particularly useful for highly basic peptides, short di- and tripeptides, and confirmation of electrophoretic purity.

Orthogonal Structural Confirmation

Where an impurity exceeds identification thresholds, isolation followed by amino acid analysis, Edman sequencing, nuclear magnetic resonance spectroscopy, or tandem MS structural elucidation is performed to unambiguously assign its structure before qualification and specification setting.

Method Validation

All quantitative methods are validated in accordance with ICH Q2(R2) for specificity, linearity, range, accuracy, precision, detection limit, quantitation limit, and robustness. Forced degradation studies under acid, base, oxidation, thermal, and photolytic stress conditions demonstrate stability-indicating capability and confirm that the method resolves all relevant degradation pathways.

Applications

Peptide related substances analysis supports the full product lifecycle across the biopharmaceutical industry:

• GMP batch release testing of peptide APIs and drug products against registered specifications
• Stability studies under ICH Q1A(R2) conditions to establish retest periods and shelf life
• Process development and optimization, including synthesis cycle design, cleavage, and purification studies
• Comparability exercises following process, site, or scale changes
• Biosimilar and generic peptide development, where impurity profiles are benchmarked against reference products
• Identification, isolation, and qualification of impurity reference standards for pharmacopoeial or internal control purposes
• Investigation of out-of-specification results and root-cause analysis of degradation events

Accredited third-party laboratories with validated platforms and GMP-compliant quality systems routinely conduct these studies, providing manufacturers with data packages suitable for regulatory submissions in multiple jurisdictions.

FAQ

What is the difference between related substances and residual impurities in peptide testing?

Related substances are structurally related to the peptide active substance, such as deletion, truncated, oxidized, or deamidated variants. Residual impurities, by contrast, are non-peptidic process residuals such as residual solvents, inorganic reagents, and cleaning agents, which are controlled through separate analytical procedures.

What impurity reporting thresholds apply to peptides?

For most new drug substances, ICH Q3A(R2) sets a reporting threshold of 0.05%, an identification threshold of 0.10%, and a qualification threshold of 0.15%, or the corresponding daily-intake-based limits where applicable. Product-specific pharmacopoeial monographs may define stricter or individually specified limits.

Why is RP-HPLC combined with mass spectrometry the preferred strategy?

RP-HPLC provides the resolution needed to separate structurally similar peptide variants at trace levels, while mass spectrometry confirms the molecular identity of each peak. This combination satisfies both quantification and identification requirements in a single, efficient workflow.

How are unknown impurities identified?

Unknown impurities exceeding identification thresholds are typically enriched by preparative chromatography, then characterized by accurate-mass MS/MS and, where necessary, sequencing or NMR. The confirmed structure supports toxicological qualification and the setting of specified impurity limits.

Can related substances analysis be outsourced?

Yes. Accredited third-party laboratories operating under ISO/IEC 17025 or GMP quality systems offer validated related substances methods, impurity identification, and stability-indicating method development, delivering regulatory-ready reports for submissions and batch release.

What sample considerations are important for accurate results?

Peptides are prone to adsorption, oxidation, and degradation during handling. Samples should be supplied in inert containers under conditions that maintain integrity, with information on formulation, counterion, storage history, and expected impurities to guide method selection and standard preparation.